Patent ID: 7888007
Filing Date: 2011-02-15
Classification: C12Q,G01N

Abstract:
1. A method of identifying a compound as a putative anti-prostate cancer or anti-breast cancer agent, the method comprising; determining the expression of a plexinB1 nucleic acid in a cell in the presence of a test compound as compared with expression of the plexinB1 nucleic acid in the cell in the absence of the test compound, wherein said plexinB1 nucleic acid comprises of AB007867.1 (SEQ ID NO:112) with at least one mutation in the coding region of the nucleic acid selected from the group consisting of C5059T, C5060T, G5074A, A5359G, T5401A, G5452A, G5458A, C5468T, A5474G, A5596G, A5653G, C5662T, A5674G, C5713T, T5714C and C5980T, wherein the mutations are numbered starting at residue 1 of AB007867.1 (SEQ ID NO:112) and; wherein a reduction in expression of the plexinB1 nucleic acid in the cell in the presence of the test compound as compared with expression of the plexinB1 nucleic acid in the cell in the absence of the test compound identifies the test compound as a putative anti-prostate cancer or anti-breast cancer agent.